Burning Rock Biotech Limited focuses on the application of next generation sequencing technology in the field of precision oncology. Its business consists of NGS-based therapy selection testing for late-stage cancer patients as well as NGS-based cancer early detection. Burning Rock Biotech Limited is based in GUANGZHOU, China.
| Revenue (Most Recent Fiscal Year) | $77.16M |
| Net Income (Most Recent Fiscal Year) | $-7.92M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.37 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.33 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -13.48% |
| Net Margin (Trailing 12 Months) | -13.60% |
| Return on Equity (Trailing 12 Months) | -12.98% |
| Return on Assets (Trailing 12 Months) | -8.59% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.05 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.90 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.73 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.28 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.87 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 10.52M |
| Free Float | 7.33M |
| Market Capitalization | $170.92M |
| Average Volume (Last 20 Days) | 0.06M |
| Beta (Past 60 Months) | 1.29 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 30.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 30.03% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |